ABCG2 Overexpression Contributes to Pevonedistat Resistance

MLN4924 (pevonedistat) is a first-in-class NEDD8-activating enzyme (NAE) inhibitor in clinical trials for the treatment of solid tumors and hematologic malignancies. Despite the promising activity of MLN4924 observed in early trials, drug resistance has been noted in some patients. Identifying the u...

Descrizione completa

Salvato in:
Dettagli Bibliografici
Pubblicato in:Cancers (Basel)
Autori principali: Kathawala, Rishil J., Espitia, Claudia M., Jones, Trace M., Islam, Shariful, Gupta, Pranav, Zhang, Yun-Kai, Chen, Zhe-Sheng, Carew, Jennifer S., Nawrocki, Steffan T.
Natura: Artigo
Lingua:Inglês
Pubblicazione: MDPI 2020
Soggetti:
Article
Accesso online:https://ncbi.nlm.nih.gov/pmc/articles/PMC7072604/
https://ncbi.nlm.nih.gov/pubmed/32059437
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12020429
Tags: Aggiungi Tag
Nessun Tag, puoi essere il primo ad aggiungerne! !

Documenti analoghi